Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting 2024-04-04 22:00
SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024 2024-04-04 01:00
Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC 2024-04-03 20:00
Ascletis Announces Strategic Decisions on FXR agonist ASC42 2024-04-03 17:10
Nagase Viita Receives Highest "Platinum" Rating for Sustainability from EcoVadis 2024-04-03 14:00
I-Mab Announces Closing of the Divestiture of Business Operations in China 2024-04-03 04:01
GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 2024-04-02 23:00
First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH 2024-04-02 20:00
Origin Agritech Provides First Half Revenue Forecast and Updates Advancements in Hybrids and GMO Development 2024-04-02 19:30
Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification 2024-04-01 21:00
Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO 2024-04-01 14:30
LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC) 2024-03-29 21:00
73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis 2024-03-29 20:40
Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) 2024-03-29 20:00
IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma 2024-03-29 17:20
Jacobio Pharma Announces 2023 Annual Results 2024-03-29 08:50
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade 2024-03-29 06:00
Harbour BioMed Reports Full Year 2023 Financial Results 2024-03-28 22:10
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma 2024-03-28 19:00
Tigermed Reports Full Year 2023 Results 2024-03-28 18:31
1 2 3 4 5 6 203